Analysis of Clinical Application and Adverse Reactions of Houttuynia Cordata Injection. The participants, interventions, comparison, outcome and study design (PICOS) criteria were used to identify articles: 1) participants: patients treated with LHQW, 2) interventions: LHQW or LHQW combined with conventional drug (LHQW capsule: Shijiazhuang Yiling Pharmaceutical Co., Ltd., National medicine approval Z20040063; LHQW granule: Shijiazhuang Yiling Pharmaceutical Co., Ltd., National medicine approval Z20100040), 3) comparison: conventional drugs, including antiviral drugs, conventional antibiotics or symptomatic treatment, 4) outcome: relevant data on adverse reactions, and 5) study design: experimental study. Li J.Y., You Z., Wang Q., Zhou Z.J., Qiu Y., Luo R., Ge X.Y. Received: 27 August 2021; Accepted: 06 January 2022;Published: 27 January 2022. Results: In total, 217 experimental studies were included. The clinical application experience of LHQW has improved over the years, the clinical considers the patients condition, physical quality, and age, controls the amount of LHQW prescribed accordingly and thereby, reduced the likelihood of adverse reactions. [14] Retraction Watch also notes that author Jia Zheng-hua is the son-in-law of Wu Yi-ling, the founder of the company in question. 04:26. Twenty-six studies focused on treatment of common pneumonia, of which 23 reported adverse reactions. doi:10.1111/j.1365-2796.1990.tb00199.x, Higgins, J. P., Altman, D. G., Gtzsche, P. C., Jni, P., Moher, D., Oxman, A. D., et al. Inhibitory effects of three prescriptions of traditional Chinese medicine on SARS-associated coronavirus, http://kns.cnki.net/kcms/detail/11.2162.R.20200422.1429.002.html. Sci.). Study design was done by CH and BH. Efficacy and safety of Lianhuaqingwen for mild or moderate : Medicine (2016). Chin. Exploring material basis and mechanism of Lianhua Qingwen prescription against coronavirus based on network pharmacology. Individuals w/ cold deficiencies in spleen & stomach or w/ qi. Secondly, separate evaluations were further performed for different diseases and types of adverse reactions. Jia W., Wang C., Wang Y., Pan G., Jiang M., Li Z., Zhu Y. Qualitative and quantitative analysis of the major constituents in Chinese medical preparation Lianhua-Qingwen capsule by UPLC-DAD-QTOF-MS. Wang C.H., Zhong Y., Zhang Y., Liu J.P., Wang Y.F., Jia W.N., Wang G.C., Li Z., Zhu Y., Gao X.M. However, no statistical difference was detected with regard to rash (RR = 0.60, 95% CI = 0.211.67) and dizziness (RR = 1.79, 95% CI = 0.339.74). 43 studies on treatment of respiratory tract infection were examined, with 29 reporting adverse reactions. Front. Retrospective clinical analysis on treatment of coronavirus disease 2019 with traditional Chinese medicine Lianhua Qingwen. BMJ. 8600 Rockville Pike Efficacy of Lianhua Qingwen Compared With Conventional Drugs in the Treatment of Common Pneumonia and Covid-19 Pneumonia: a Meta-Analysis. The current. Lianhua Qingwen Dosage & Drug Information | MIMS Thailand The results of quantitative analyses are presented in Table 1 and the statistical significance of Forest plots shown in Supplementary Figure S1. [citation needed]. It was demonstrated that the use of LHQW also brought the incidence of gastrointestinal reactions, as well as skin and its accessories injuries, including diarrhea, abdominal distension, gastrointestinal discomfort, rash, and itching, despite the low quality of the included documents [50,51]. Management of adverse reactions was clearly documented in 38 studies, which reported improvement or resolution through discontinuation of medication, changes to post-meal administration, symptomatic or no treatment. Lianhua Qingwen (LHQW) is a commonly used Chinese medical preparation to treat viral influenza, including in the fight against SARS in 20022003 in China. Drugs and Clinic. Reports emerged indicating that this process consumed significant logistical capacity, drawing criticism about misuse of resources at a time when people were struggling with shortages of basic needs such as food and medication. Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease. Homogeneity of baseline data was reported in most studies. 13 (08), 676681. A multicenter retrospective study showed similar results, which revealed that combined application of LHQW granules (6g, tid) could notably improve the clinical symptoms of fever, fatigue, cough, expectoration, chest tightness, and anorexia, and reduce the proportion of common to severe cases in COVID-19 patients with common type [20]. We observed no significant alteration in the security evaluation indexes of treatment among different diseases. Heterogeneity was evaluated using I2 statistic. Cui L.F., Xu H.R., Li F.Z., Wang C.X. Therefore, further attention should be paid to the occurrence of adverse reaction with LHQW among different age groups in the future. 6 (26), 8485. J. Nanjing Univ. (1990). The Cochrane Collaboration risk of bias tool comprising seven items was applied to assess the risk of bias of each eligible study (Higgins et al., 2011). Academician Yiling Wu systematically constructs the theory of collateral disease, provides theoretical guidance for the formulation of Lianhua Qingwen, and gives . Business China. Royal Botanic Gardens, Kew (2021). LHQW is recommended by the National Health Commission of the Peoples Republic of China as a traditional Chinese medicine appropriate for COVID-19 pneumonia (trial version from Fourth to the Eighth Edition). Experimental study on prevention and treatment of influenza virus FM1 infection in mice by Lianhua Qingwen capsule. Control. Pharmacol. Beijing: China Medical Science Press. There was no statistically significant difference in the incidence of adverse reactions during treatment of COVID-19 pneumonia between the LHQW group and the conventional drug group (RR = 0.51, 95% CI = 0.141.82, p = 0.297). In the evaluation of treating disease, the incidence of adverse reactions during treatment of influenza A (H1N1) and influenza were lower in the LHQW group compared to the conventional drug group. (2021). Figure 1 provides a detailed flowchart of the screening process. Case reports, unrelated studies, those with duplicate data, reviews, commentaries and animal-based studies were excluded from the current meta-analysis. From SARS to COVID-19: pathogens, receptor, pathogenesis and principles of the treatment. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. The recent meta analysis reported 22 studies with a total of 2,007 patients, showing that the adjuvant therapy of LHQW with western medicine could improve the clinical efficiency and C-reactive protein index, shorten the time of antifebrile, cough time, rhondros duration and imaging time, as well as speed up the recovery of pneumonia patients [39]. Asia-Pacific Traditional Med. Further evaluation revealed that LHQW significantly inhibited SARS-CoV-2 replication in Vero E6 cells, markedly reduced pro-inflammatory cytokines (TNF-, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) production and resulted in abnormal particle morphology of virion in cells [30]. These data indicate that LHQW prescription protects against the virus attack, and it has been recommended in the treatment of COVID-19 in China [47]. doi:10.13422/j.cnki.syfjx.20201099, Ye, C., Gao, M., Lin, W., Yu, K., Li, P., and Chen, G. (2020). [9], During the COVID-19 pandemic, the government of the People's Republic of China (PRC) approved the use of Lianhua Qingwen for mild to moderate COVID-19 cases in January 2020, and promotes the use of the medicine abroad. There was no statistically significant difference in the incidence of adverse reactions during treatment of rheum between the LHQW group and the conventional drug group (RR = 0.46, 95% CI = 0.121.83, p = 0.270). 2020, 5157089. doi:10.1155/2020/5157089, Huang, N. L., Huang, H. M., Zhang, B. Y., and Xie, J. Statistical analysis was performed with Stata 14 software (Stata Corporation, College Station, TX, USA). LHQW is composed of 11 herbs including Forsythia suspensa (Thunb.) Lu Y., Yang J., Wang X., Ma Z., Li S., Liu Z., Fan X. Wang Z., Chen X., Lu Y., Chen F., Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and western medicine treatment. Further investigation confirmed that the combination treatment of LHQW capsules (200mg/kg/day) with oseltamivir (2mg/kg/day) markedly reduced IBV infection over the individual administration of either alone in vivo, proving that LHQW capsules could be used as an assistant drug to enhance the effect of oseltamivir against IBV infection [26].
Dave Amato Family,
Richland Bombers Logo,
Lhsaa Softball Mercy Rule,
Baby Head Measuring Small On Ultrasound Forum,
Articles L
